Fulgent Genetics, Inc.

Equities

FLGT

US3596641098

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2024 am IST			5-day change	1st Jan Change
23.31 ^USD	+6.58%		+18.93%	-19.37%

01/07	Fulgent Genetics, Inc.(NasdaqGM:FLGT) dropped from Russell 2000 Value-Defensive Index	CI
01/07	Fulgent Genetics, Inc.(NasdaqGM:FLGT) dropped from Russell 2000 Defensive Index	CI

Fulgent Genetics, Inc. acquired Airport Plaza in El Monte from TDA Investment Group for $15.4 million.

January 18, 2021

Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquired Airport Plaza in El Monte from TDA Investment Group for $15.4 million during the fourth quarter of 2020. Fulgent Genetics, Inc. (NasdaqGM:FLGT) completed the acquisition of Airport Plaza in El Monte from TDA Investment Group during the fourth quarter of 2020.

Latest news about Fulgent Genetics, Inc.

Fulgent Genetics, Inc.(NasdaqGM:FLGT) dropped from Russell 2000 Value-Defensive Index	01/07	CI
Fulgent Genetics, Inc.(NasdaqGM:FLGT) dropped from Russell 2000 Defensive Index	01/07	CI
Transcript : Fulgent Genetics, Inc., Q1 2024 Earnings Call, May 03, 2024	03/05
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022.	03/05	CI
Earnings Flash (FLGT) FULGENT GENETICS Posts Q1 Revenue $64.5M	03/05	MT
Fulgent Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Year 2024	03/05	CI
Piper Sandler Adjusts Price Target on Fulgent Genetics to $25 From $28, Maintains Neutral Rating	06/03	MT
UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating	29/02	MT
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022.	29/02	CI
Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024	28/02	CI
Transcript : Fulgent Genetics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	28/02
Fulgent Genetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02	CI
Earnings Flash (FLGT) FULGENT GENETICS Reports Q4 Revenue $70.5M	28/02	MT
Earnings Flash (FLGT) FULGENT GENETICS Reports Q4 EPS $0.28	28/02	MT
Cooper Unit, Fulgent Genetic to Offer Newborn Genetic Screening Panels	09/02	MT
Cord Blood Registry by CooperSurgical, Inc. and Fulgent Genetics, Inc. Launch Innovative Genetic Testing	09/02	CI
UBS Initiates Coverage on Fulgent Genetics With Neutral Rating, $35 Price Target	07/12	MT
Fulgent Genetics, Inc. Announces Two Poster Presentations At SITC 2023 Annual Meeting	04/11	CI
Transcript : Fulgent Genetics, Inc., Q3 2023 Earnings Call, Nov 03, 2023	03/11
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022.	03/11	CI
Fulgent Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11	CI
Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2023	03/11	CI
Insider Sell: Fulgent Genetics	31/23/31	MT
Sector Update: Health Care Stocks Steady Premarket Friday	04/23/04	MT

Chart Fulgent Genetics, Inc.

Duration

Period

More charts

Company Profile

Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Companyâs laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.

Sector

Healthcare Facilities & Services

Calendar

02/08/2024 - Q2 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Fulgent Genetics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

21.87 USD

Average target price

26.67 USD

Spread / Average Target

+21.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
FULGENT GENETICS, INC.	-19.37%	65Cr
SONIC HEALTHCARE LIMITED	-16.93%	847.77Cr
RADNET, INC.	+79.26%	481.4Cr
DR. LAL PATHLABS LIMITED	+16.31%	298.55Cr
SYNLAB AG	-3.15%	264.52Cr
NEOGENOMICS, INC.	-4.20%	202.3Cr
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-52.37%	187.1Cr
FLEURY S.A.	-13.53%	157.95Cr
METROPOLIS HEALTHCARE LIMITED	+21.59%	125.09Cr
DIAN DIAGNOSTICS GROUP CO.,LTD.	-47.00%	105.66Cr

Medical & Diagnostic Laboratories